The emerging role of galectin-3 and ST2 in heart failure: Practical considerations and pitfalls using novel biomarkers

被引：27

作者：

Karayannis G. ^{[1
]}

Triposkiadis F. ^{[1
]}

Skoularigis J. ^{[1
]}

Georgoulias P. ^{[2
]}

Butler J. ^{[3
]}

Giamouzis G. ^{[1
]}

机构：

[1] Department of Cardiology, University Hospital of Larissa, University of Thessaly, 411 10 Larissa

[2] Department of Nuclear Medicine, University Hospital of Larissa, University of Thessaly, Larissa

[3] Emory University, Atlanta, GA

来源：

Current Heart Failure Reports | 2013年 / 10卷 / 4期

关键词：

Biomarkers; Galectin-3; Heart failure; sST2;

D O I：

10.1007/s11897-013-0169-1

中图分类号：

学科分类号：

摘要：

Heart failure (HF) is a leading cause of morbidity and mortality worldwide and, despite recent advances in therapy HF hospitalization rates remains unacceptably high. Prompt identification and optimal management of HF can affect long-term outcome. A valuable tool with diagnostic, prognostic, and treatment-guiding properties in this respect will be very useful, as exemplified by natriuretic peptides. However, natriuretic peptide levels show biological variation and are dependent on age, renal function, and body mass index. Recent advances in the field of molecular biology and HF pathophysiology have led to the discovery of other novel biomarkers that may have advantages. Among others, Galectin-3 (GAL3) and sST2 are 2 promising biomarkers that have been recently developed and can be used alone or in combination with natriuretic peptides in clinical practice. In the current paper, we review the existing data regarding GAL3 and sST2 in HF. © 2013 Springer Science+Business Media New York.

引用

页码：441 / 449

页数：8

共 93 条

[1]

Sherwi N., Merali S., Wong K., Personalizing biomarker strategies in heart failure with galectin-3, Future Cardiol, 8, 6, pp. 885-894, (2012)

[2]

Lloyd-Jones D., Adams R., Carnethon M., De Simone G., Ferguson T.B., Flegal K., Et al., Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, 119, 3, pp. 480-486, (2009)

[3]

Giamouzis G., Kalogeropoulos A., Georgiopoulou V., Laskar S., Smith A.L., Dunbar S., Et al., Hospitalization epidemic in patients with heart failure: Risk factors, risk prediction, knowledge gaps, and future directions, J Cardiac Failure, 17, 1, pp. 54-75, (2011)

[4]

Wu A.H., Wians F., Jaffe A., Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implication on interpretation of test results, Am Heart J, 165, 6, pp. 995-999, (2013)

[5]

Rehman S.U., Mueller T., Januzzi Jr.J.L., Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure, J Am Coll Cardiol, 52, 18, pp. 1458-1465, (2008)

[6]

De Boer R.A., Yu L., Van Veldhuisen D.J., Galectin-3 in cardiac remodeling and heart failure, Curr Heart Failure Rep, 7, 1, pp. 1-8, (2010)

[7]

Rosenberg I., Cherayil B.J., Isselbacher K.J., Pillai S., Mac-2-binding glycoproteins. Putative ligands for a cytosolic beta-galactoside lectin, J Biol Chem, 266, 28, pp. 18731-18736, (1991)

[8]

Sato S., Hughes R.C., Binding specificity of a baby hamster kidney lectin for H type i and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin, J Biol Chem, 267, 10, pp. 6983-6990, (1992)

[9]

Kim H., Lee J., Hyun J.W., Park J.W., Joo H.G., Shin T., Expression and immunohistochemical localization of galectin-3 in various mouse tissues, Cell Biol Int, 31, 7, pp. 655-662, (2007)

[10]

Hattasch R., Spethmann S., De Boer R.A., Ruifrok W.P., Schattke S., Wagner M., Et al., Galectin-3 increase in endurance athletes, Eur J Prev Cardiol, (2013)

← 1 2 3 4 5 6 7 8 9 10 →